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1. Introduction {#sec1}
===============

In December 2019, the Wuhan Municipal Health Commission, China, reported a cluster of a pneumonia-like illness, caused by a coronavirus (SARS-CoV-2) in Wuhan, Hubei Province of China ([@bib21]; [@bib29]; [@bib32]). The disease rapidly spread to many countries, resulting in the [@bib32] declaring the novel coronavirus (COVID-19) as a pandemic on March 11, 2020 ([@bib24]; [@bib29]; [@bib32]). As of June 28, 2020, COVID-19 has caused over 10 million confirmed cases and 500,000 fatalities globally. The United States, which is now the epicenter of COVID-19, recorded over 2.5 million confirmed cases and 125,000 deaths ("[@bib5]). While some people infected with COVID-19 experience mild symptoms of the disease (such as fever, coughing and shortness of breath), others develop severe disease and complications (causing acute respiratory failure, which damages the lungs and often cause death) ([@bib19]; [@bib24]; [@bib31]). In addition to the devastating public health burden it induced in the US, COVID-19 has also inflicted severe economic hardship, causing a decrease in both human and economic productivity (translating to about 30% unemployment rate, and a projected 50% decline in GDP by the summer of 2020 ([@bib22]; [@bib26])).

There are currently no approved vaccines and effective therapies for use against COVID-19. Hence, control efforts against COVID-19 are focused on using basic non-pharmaceutical interventions (NPIs), such as social distancing, quarantine of people suspected of being exposed to COVID-19, isolation of confirmed cases, use of face masks in public and contact-tracing ([@bib24]; [@bib14]; [@bib13]). There is now a concerted global effort to develop a safe and effective anti-COVID-19 vaccine to help combat the COVID-19 pandemic. Although the development of new vaccines generally take years, a number of pharmaceutical companies, with support from numerous government agencies and regulatory authorities, are doing everything possible to fast-track the availability of a safe and effective vaccine against COVID-19. Over a dozen organizations have announced plans to start efficacy testing for their candidate vaccines ([@bib19]; [@bib4]; [@bib18]). In fact, scientists at the Jenner Institute at the Oxford University have developed a new coronavirus vaccine that is undergoing early-phase trials, and they expect the first few million doses of their vaccine to be widely available as early as September 2020 ([@bib4]; [@bib18]). A Maryland-based biotechnology company *Novavax* has begun human clinical trials for its candidate vaccine in Australia ([@bib19]). Similarly, *Mesoblast*, a company supported by the 10.13039/100000002National Institutes of Health (10.13039/100000002NIH), started a 240-patient clinical trial aimed at testing whether cells derived from bone marrow could help patients who developed a deadly immune reaction to the coronavirus ([@bib19]). Thus, there is an urgent need to develop and use mathematical models to assess the population-level impact of a future hypothetical vaccine against COVID-19. This forms the objective of the current study.

Numerous mathematical models have been developed and used to study the transmission dynamics and control of COVID-19. For instance, an agent-based model was developed by Ferguson et al. ([@bib14]) to investigate the impact of NPIs on COVID-19-induced mortality, showing an alarming worst-case projection of number of cases for the US and Great Britain (at the tune of 81%). Eikenberry et al. ([@bib13]) developed a multi-group model for assessing the community-wide impact of mask use by the general, asymptomatic public, a portion of which may be asymptomatically-infectious. The study shows that the use of face masks by members of the general public is potentially of high value in curtailing community transmission and the burden of the pandemic, and that the community-wide benefits are likely to be greatest when face masks are used in conjunction with other non-pharmaceutical practices (such as social distancing), and when adoption is nearly universal (nation-wide) and compliance is high. Ngonghala et al. ([@bib24]) developed a comprehensive model for assessing the impact of the major NPIs (quarantine, isolation, social distancing, face mask usage in public, testing and contact-tracing) on the control of COVID-19. Their study estimated that, while the early relaxation or lifting social distancing measures and mask usage is likely to lead to second wave, the extended adherence to the current social distancing and mask usage can significantly reduce COVID-induced mortality in the US in general, and the state of New York in particular.

Mizumoto and Chowell ([@bib23]) modeled the potential for a COVID-19 outbreak in the Diamond Princess cruise ship. Their study showed an estimate of a higher reproduction number, which substantially decreases with increasing effectiveness of quarantine measures on the ship. A stochastic model was developed by Hellewell et al. ([@bib16]) to assess the impact of contact-tracing and isolation on disease control. Their study suggests that (for most instances) the spread of COVID-19 can be effectively contained in 3 months if the two control measures (contact-tracing and isolation) are highly effective. Kucharski et al. ([@bib20]) also developed a stochastic model to assess the COVID-19 trajectory in Wuhan from January to February 2020, showing a reduction in transmission when travel restrictions were implemented. Li et al. developed a mathematical model to assess the effect of mass influenza vaccination on the spread of COVID-19 and other influenza-like pathogens co-circulating during an influenza season. Their study showed that increasing influenza vaccine uptake, or enhancing the public health interventions, would facilitate the management of outbreaks of respiratory pathogens circulating during the peak flu season.

The current study is based on the design of a mathematical model to assess the impact of an anti-COVID-19 vaccine on the transmission dynamics of the COVID-19 pandemic in the United States. COVID-19 mortality data for the US will be used to fit the model, and to estimate the unknown parameters of the model (notably the contact rate parameters).

2. Materials and methods {#sec2}
========================

2.1. Model formulation {#sec2.1}
----------------------

This study is based on the development of a relatively standard mathematical model for assessing the population-level impact of a potential hypothetical anti-COVID-19 vaccine in a community. The model is developed by splitting the total human population at time *t*, denoted by $N\left( t \right)$, into the mutually-exclusive compartments of unvaccinated susceptible ($S_{u}\left( t \right))$, vaccinated susceptible ($S_{v}\left( t \right))$, early-exposed ($E_{1}\left( t \right)$; i.e., newly-exposed individuals), pre-symptomatic infectious ($E_{2}\left( t \right)$), symptomatically-infectious ($I_{s}\left( t \right)$, asymptomatically-infectious ($I_{a}\left( t \right))$, hospitalized ($I_{h}\left( t \right))$ and recovered ($R\left( t \right))$ individuals. Thus,$$N\left( t \right) = S_{u}\left( t \right) + S_{v}\left( t \right) + E_{1}\left( t \right) + E_{2}\left( t \right) + I_{s}\left( t \right) + I_{a}\left( t \right) + I_{h}\left( t \right) + R\left( t \right).$$

It should be emphasized that individuals in the $E_{2}$ compartment are those newly-infected individuals that are close to surviving the incubation period, and are shedding the virus. Hence, they are infectious (i.e., they are able to transmit COVID-19 infection to susceptible individuals). Furthermore, while individuals in the $I_{s}$ are those that show moderate to severe symptoms of COVID-19 at the end of the incubation period, those in the $I_{a}$ compartment are assumed to show mild or no clinical symptoms of the disease at the end of the incubation period. The compartment $I_{h}$ also contains individuals with clinical symptoms of COVID-19 who are hospitalized or self-isolated at home.

The model is given by the following deterministic system of nonlinear differential equations, where a dot represents differentiation with respect to time *t* (a flow diagram of the model is depicted in [Fig. 1](#fig1){ref-type="fig"}. The state variables and parameters of the model are described in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, respectively):$$\begin{array}{lll}
{\overset{˙}{S}}_{u} & = & {- \left( {\lambda_{e} + \lambda_{s} + \lambda_{a}} \right)S_{u} - \xi_{v}S_{u},} \\
{\overset{˙}{S}}_{v} & = & {\xi_{v}S_{u}\  - \left( {1 - \varepsilon_{v}} \right)\left( {\lambda_{e} + \lambda_{s} + \lambda_{a}} \right)S_{v},} \\
{\overset{˙}{E}}_{1} & = & {\left( {\lambda_{e} + \lambda_{s} + \lambda_{a}} \right)\left\lbrack S_{u} + \left( {1 - \varepsilon_{v}} \right)S_{v} \right\rbrack - \sigma_{1}E_{1},} \\
{\overset{˙}{E}}_{2} & = & {\sigma_{1}E_{1} - \sigma_{2}E_{2},} \\
{\overset{˙}{I}}_{s} & = & {\left( {1 - r} \right)\ \sigma_{2}\ E_{2} - \left( {\phi_{s} + \gamma_{s} + \delta_{s}} \right)I_{s},} \\
{\overset{˙}{I}}_{a} & = & {r\ \sigma_{2}\ E_{2} - \gamma_{a}I_{a},} \\
{\overset{˙}{I}}_{h} & = & {\phi_{s}I_{s} - \left( {\gamma_{h} + \delta_{h}} \right)I_{h},} \\
\overset{˙}{R} & = & {\gamma_{s}I_{s} + \gamma_{a}I_{a} + \gamma_{h}I_{h},} \\
\end{array}$$where the *forces of infection* $\lambda_{e},\ \lambda_{s}$ and $\lambda_{a}$ are defined below$$\lambda_{e} = \beta_{e}\left( {1 - \varepsilon_{M}c_{M}} \right)\frac{E_{2}}{N},\ \lambda_{s} = \beta_{s}\left( {1 - \varepsilon_{M}c_{M}} \right)\frac{I_{s}}{N},\ \lambda_{a} = \beta_{a}\left( {1 - \varepsilon_{M}c_{M}} \right)\frac{I_{a}}{N}.$$Fig. 1Flow diagram of the model (2.1).Fig. 1Table 1Description of state variables of the model (2.1).Table 1**State variableDescription**$S_{u}$Population of unvaccinated susceptible individuals$S_{v}$Population of vaccinated susceptible individuals$E_{1}$Population of early-exposed individuals (i.e., newly-infected individuals who are not yet infectious)$E_{2}$Population of pre-symptomatic infectious individuals (i.e., exposed individuals who are close to surviving the incubation period and are shedding virus)$I_{s}$Population of symptomatically-infectious individuals (who display moderate or severe symptoms of the disease at the end of the incubation period)$I_{a}$Population of asymptomatically-infectious individuals (who display mild or no clinical symptoms of the disease at the end of the incubation period)$I_{h}$Population of hospitalized individuals*R*Population of recovered individualsTable 2Description of the parameters of the model (2.1).Table 2**ParameterDescription**$\beta_{e}\left( \beta_{s} \right)\left( \beta_{a} \right)$Effective community contact rate (a measure of social distancing effectiveness)$c_{M}$Proportion of members of public who wear masks in public (i.e., face masks compliance)$\varepsilon_{M}$Efficacy of face masks to prevent acquisition of infection by susceptible individuals$\xi_{v}$Vaccination rate$\varepsilon_{v}$Vaccine efficacy against acquisition of infection (degree protection)rProportion of pre-symptomatic individuals who do not show clinical symptoms of COVID-19 at the end of the incubation period$1 - r$Proportion of pre-symptomatic infectious individuals who show clinical symptoms of COVID-19 at the end of the incubation period$\sigma_{1}$Rate of progression from early-exposed class ($E_{1}$) to the pre-symptomatic class$r\sigma_{2}$Rate of progression from pre-symptomatic class ($E_{2}$) to asymptomatically-infectious class$\left( {1 - r} \right)\sigma_{2}$Rate of progression from pre-symptomatic class ($E_{2}$) to symptomatically-infectious class$\varphi_{s}$Hospitalization rate for infectious individuals$\gamma_{s}\left( \gamma_{a} \right)\left( \gamma_{h} \right)$Recovery rate for individuals in the $I_{s}\left( I_{a} \right)\left( I_{h} \right)$ class$\delta_{s}\left( \delta_{h} \right)$Disease-induced mortality rate for infectious individuals in the $I_{s}\left( I_{h} \right)$ class

In the model (2.1), unvaccinated susceptible individuals acquire COVID-19 infection, following effective contacts with individuals in the $E_{2}$, $I_{a}$ and $I_{s}$ classes, at the rates $\lambda_{e}$, $\lambda_{s}$ and $\lambda_{a}$, respectively. Unvaccinated susceptible individuals are vaccinated at a *per capita* rate $\xi_{v}$. It is assumed that the hypothetical anti-COVID-19 vaccine is imperfect. Hence, the vaccine allows for breakthrough infected in vaccinated susceptible individuals who became infected with COVID-1), with a protective efficacy $0 < \varepsilon_{v} \leq 1$ (i.e., vaccinated susceptible individuals are assumed to acquire COVID-19 infection, following effective contact with individuals in the $E_{2}$, $I_{s}$ and $I_{a}$ classes at the reduced rates, $\left( {1 - \varepsilon_{v}} \right)\lambda_{e}$, $\left( {1 - \varepsilon_{v}} \right)\lambda_{s}$ and $\left( {1 - \varepsilon_{v}} \right)\lambda_{a}$, respectively).

The parameter $\sigma_{1}$ represents the progression rate of individuals in the early-exposed class (i.e., individuals in the $E_{1}$ class) to the pre-symptomatic infectious class ($E_{2}$). Similarly, $\sigma_{2}$ is the rate at which pre-symptomatic individuals progress, at the end of the incubation period, to either the asymptomatically-infectious class, $I_{a}$ (at a rate $r\sigma_{2}$; where $0 < r \leq 1$ is the proportion of pre-symptomatic infectious individuals who do not show clinical symptoms of COVID-19 at the end of the incubation period) or to the symptomatically-infectious class, $I_{s}$ (at a rate $\left( {1 - r} \right)\sigma_{2}$). Thus, the intrinsic incubation period of COVID-19 is given by $\frac{1}{\sigma_{1}} + \frac{1}{\sigma_{2}}$. The parameter $\gamma_{s}\left( \gamma_{a} \right)\left( \gamma_{h} \right)$ represents the recovery rate for individuals in the $I_{s}\left( I_{a} \right)\left( I_{h} \right)$ class. Similarly, $\varphi_{s}$ is the hospitalization (or self-isolation) rate of individuals with clinical symptoms of COVID-19. Finally, the parameter $\delta_{s}\left( \delta_{h} \right)$ represents the COVID-induced mortality rate for individuals in the $I_{s}\left( I_{h} \right)$ class. It should be mentioned that, since not much data is available on the expected properties of a future anti-COVID-19 vaccine, we do not assume that the vaccine offers any therapeutic benefits. Further, we do not assume that the vaccine wanes during the one-year time period we would choose for the numerical simulations of our model.

In [(2.2)](#fd2_2){ref-type="disp-formula"}, the parameter $\beta_{e}\left( \beta_{s} \right)\left( \beta_{a} \right)$ represents the effective contact rate (i.e., contacts capable of leading to COVID-19 transmission) for pre-symptomatically-infectious (symptomatically-infectious) (asymptomatically-infectious) individuals, $0 < c_{M} \leq 1$ is the proportion of members of the public who wear face masks (correctly and consistently) in public and $0 < \varepsilon_{M} \leq 1$ is the efficacy of the face masks. This formulation (i.e., $\beta_{e} \neq \beta_{s} \neq \beta_{a}$) allows us to account for the possible heterogeneity in the contact rates of infectious individuals in the pre-symptomatic ($E_{2}$), symptomatic ($\left. I_{s} \right)$ and asymptomatic ($I_{a}$) classes. The basic model (2.1) may be the first to explicitly incorporates a hypothetical imperfect vaccine in a deterministic modeling study on COVID-19 dynamics.

It is convenient, for housekeeping purposes, to define the following equation for the rate of change of the population of COVID-deceased individuals in the community (denoted by $D\left( t \right))$:$$\overset{˙}{D} = \delta_{s}I_{s} + \delta_{h}I_{h}.$$

3. Theoretical analysis {#sec3}
=======================

3.1. Asymptotic stability of disease-free equilibria {#sec3.1}
----------------------------------------------------

The model (2.1) has a continuum (or line) of disease-free equilibria (DFE), given by$$\mathcal{E}_{0}:\ \left( {S_{u}^{\text{∗}},\ S_{v}^{\text{∗}},\ E_{1}^{\text{∗}},\ E_{2}^{\text{∗}},\ I_{s}^{\text{∗}},\ I_{a}^{\text{∗}},\ I_{h}^{\text{∗}},\ R^{\text{∗}}} \right) = \left( {N\left( 0 \right) - \left( {S_{v}^{\text{∗}} + R^{\text{∗}}} \right),\ S_{v}^{\text{∗}},\ 0,\ 0,\ 0,\ 0,0,R^{\text{∗}}} \right),$$where $N\left( 0 \right)$ is the initial total population size, $S_{v}^{\text{∗}} > 0,R^{\text{∗}} > 0,$ and $0 \leq S_{v}^{\text{∗}} + R^{\text{∗}} \leq N\left( 0 \right) = N^{\text{∗}}$. The next generation operator method ([@bib12]; [@bib9]) can be used to analyse the asymptotic stability property of the continuum of disease-free equilibria, $\mathcal{E}_{0}$. In particular, using the notation in ([@bib12]), it follows that the associated next generation matrices, *F* and *V*, for the new infection terms and the transition terms, are given, respectively, by$${F = \begin{bmatrix}
0 & A_{e} & A_{s} & A_{a} \\
0 & 0 & 0 & 0 \\
0 & 0 & 0 & 0 \\
0 & 0 & 0 & 0 \\
\end{bmatrix}},$$and,$$V = \begin{bmatrix}
\sigma_{1} & {0} & {0} & {0} \\
{- \sigma_{1}} & \sigma_{2} & 0 & 0 \\
0 & {- \left\lbrack {1 - r} \right\rbrack\sigma_{2}} & {\varphi_{s} + \gamma_{s} + \delta_{s}} & 0 \\
0 & {- r\sigma_{2}} & 0 & \gamma_{a} \\
\end{bmatrix},$$where,$$\begin{array}{lll}
A_{e} & = & {\beta_{e}\left( {1 - \varepsilon_{M}c_{M}} \right)\left\lbrack \frac{S_{u}^{\text{∗}} + \left( {1 - \varepsilon_{v}} \right)S_{v}^{\text{∗}}}{N^{\text{∗}}} \right\rbrack,} \\
A_{s} & = & {\beta_{s}\left( {1 - \varepsilon_{M}c_{M}} \right)\left\lbrack \frac{S_{u}^{\text{∗}} + \left( {1 - \varepsilon_{v}} \right)S_{v}^{\text{∗}}}{N^{\text{∗}}} \right\rbrack,} \\
A_{a} & = & {\beta_{a}\left( {1 - \varepsilon_{M}c_{M}} \right)\left\lbrack \frac{S_{u}^{\text{∗}} + \left( {1 - \varepsilon_{v}} \right)S_{v}^{\text{∗}}}{N^{\text{∗}}} \right\rbrack.} \\
\end{array}$$

It is convenient to define the quantity $\mathcal{R}_{c}$ by (with ρ being the spectral radius):$$\mathcal{R}_{c} = \rho\left( {FV^{- 1}} \right) = \mathcal{R}_{E_{2}} + \mathcal{R}_{I_{s}} + \mathcal{R}_{I_{a}},$$where,$$\begin{array}{lll}
\mathcal{R}_{E_{2}} & = & {\frac{\beta_{e}\left( {1 - \varepsilon_{M}c_{M}} \right)}{\sigma_{2}}\left\lbrack \frac{S_{u}^{\text{∗}} + \left( {1 - \varepsilon_{v}} \right)S_{v}^{\text{∗}}}{N^{\text{∗}}} \right\rbrack,} \\
\mathcal{R}_{I_{s}} & = & {\frac{\beta_{s}\left( {1 - r} \right)\left( {1 - \varepsilon_{M}c_{M}} \right)}{\phi_{s} + \gamma_{s} + \delta_{s}}\left\lbrack \frac{S_{u}^{\text{∗}} + \left( {1 - \varepsilon_{v}} \right)S_{v}^{\text{∗}}}{N^{\text{∗}}} \right\rbrack,} \\
\mathcal{R}_{I_{a}} & = & {\frac{\beta_{a}\ r\left( {1 - \varepsilon_{M}c_{M}} \right)}{\gamma_{a}}\left\lbrack \frac{S_{u}^{\text{∗}} + \left( {1 - \varepsilon_{v}} \right)S_{v}^{\text{∗}}}{N^{\text{∗}}} \right\rbrack.} \\
\end{array}$$

The quantity $\mathcal{R}_{c}$ is the *control reproduction number* of the model (2.1). It measures the average number of new COVID-19 cases generated by a typical infectious individual introduced into a population where a certain fraction wears face masks in public and/or are vaccinated using the hypothetical imperfect vaccine. It is the sum of the constituent reproduction numbers associated with the number of new cases generated by pre-symptomatically-infectious humans ($\left. \mathcal{R}_{E_{2}} \right)$, symptomatically-infectious humans ($\left. \mathcal{R}_{I_{s}} \right)$, and asymptomatically-infectious ($\left. \mathcal{R}_{I_{a}} \right)$ individuals. The reproduction number $\mathcal{R}_{c}$ is epidemiologically interpreted below.

### 3.1.1. Interpretation of the control reproduction number {#sec3.1.1}

As stated above, the control reproduction number $\mathcal{R}_{c}$ is the sum of the three constituent reproduction numbers, $\mathcal{R}_{E_{2}}$, $\mathcal{R}_{I_{s}}$, and $\mathcal{R}_{I_{a}}$. The constituent reproduction number $\mathcal{R}_{E_{2}}$ is given by the product of the infection rate of unvaccinated and vaccinated susceptible individuals by pre-symptomatically-infectious humans (near the continuum of disease-free equilibria), $\left\lbrack {\beta_{e}\left( {1 - \varepsilon_{M}c_{M}} \right)\left( \frac{S_{u}^{\text{∗}} + \left( {1 - \varepsilon_{v}} \right)S_{v}^{\text{∗}}}{N^{\text{∗}}} \right)} \right\rbrack$, the proportion of exposed individuals that survived the pre-exposed period and moved to the pre-symptomatically-infectious class and the average duration in the pre-symptomatically-infectious class $\left( \frac{1}{\sigma_{2}} \right)$. Similarly, the constituent reproduction number $\mathcal{R}_{I_{s}}$ is given by the product of the infection rate of unvaccinated and vaccinated susceptible individuals by symptomatically-infectious humans (near the continuum of disease-free equilibria), $\left\lbrack {\beta_{s}\left( {1 - \varepsilon_{M}c_{M}} \right)\left( \frac{S_{u}^{\text{∗}} + \left( {1 - \varepsilon_{v}} \right)S_{v}^{\text{∗}}}{N^{\text{∗}}} \right)} \right\rbrack$, the proportion of exposed individuals that survived the incubation period and moved to the symptomatically-infectious class $\left( {\frac{\left( {1 - r} \right)\sigma_{2}}{\sigma_{2}} = 1 - r} \right)$ and the average duration in the asymptomatically-infectious class $\left( \frac{1}{\varphi_{s} + \gamma_{s} + \delta_{s}} \right)$. Finally, the constituent reproduction number $\mathcal{R}_{I_{a}}$ is given by the product of the infection rate of unvaccinated and vaccinated susceptible individuals (near the continuum of disease-free equilibria), $\left\lbrack {\beta_{a}\left( {1 - \varepsilon_{M}c_{M}} \right)\left( \frac{S_{u}^{\text{∗}} + \left( {1 - \varepsilon_{v}} \right)S_{v}^{\text{∗}}}{N^{\text{∗}}} \right)} \right\rbrack$, the proportion that survived the exposed class and moved to the asymptomatically-infectious class $\left( {\frac{r\sigma_{2}}{\sigma_{2}} = r} \right)$ and the average duration in the $I_{a}$ class $\left( \frac{1}{\gamma_{a}} \right)$. The sum of $\mathcal{R}_{E_{2}}$, $\mathcal{R}_{I_{s}}$, and $\mathcal{R}_{I_{a}}$ gives. $\mathcal{R}_{c}.$

The result below follows from the next generation matrix operator method of ([@bib12]).Theorem 3.1*The continuum of disease-free equilibria* ($\mathcal{E}_{0}$) *of the model* (2.1) *is locally-asymptotically stable if* $\mathcal{R}_{c} < 1$. *If* $\mathcal{R}_{c} > 1$, *the epidemic first grows*, *reaches a peak*, *and then decreases to zero as* $\left. t\rightarrow\infty \right.$.

The epidemiological implication of [Theorem 3.1](#enun_Theorem_3_1){ref-type="statement"} is that a small influx of COVID-19 cases will not generate a COVID-19 outbreak if the control reproduction number $\left( \mathcal{R}_{c} \right)$ is less than unity (i.e., the epidemic dies out rapidly whenever $\mathcal{R}_{c} < 1$). It should be mentioned that, for epidemic models such as (2.1), the epidemiological requirement $\mathcal{R}_{c} < 1$ is only sufficient, but not necessary, for the elimination of the epidemic. This is owing to the fact that, for such models (i.e., Kermack-McKendrick epidemic models with no vital/demographic dynamics), the disease always dies out with time (regardless of the value of the reproduction number of the models). In other words, even if $\mathcal{R}_{c}$ exceeds unity, the disease will eventually die out. This is because (if $\mathcal{R}_{c} > 1$), the epidemic rises (exponentially, initially) and reach a peak. Subsequently, a combination of factors, such as the implementation of control measures in the community and the natural infection-acquired immunity in the community, will greatly curtail the epidemic to the extent that sustained community transmission is not feasible (and the disease dies out) ([@bib25]). It is worth stressing that, in the formulation of the model (2.1), we assumed that individuals who survived the COVID-19 infection develop permanent natural immunity against future COVID-19 infection (since there is no transition from the recovered to the susceptible class in the model). This natural immunity builds up in the community and contributes in protecting the rest of the susceptible population from acquiring COVID-19 infection. If recruitment of susceptible individuals is allowed (e.g., in the case where an endemic model is used), the disease will persist in the population when $\mathcal{R}_{c} > 1$ (this is because the pool of new completely-susceptible, or COVID-19-naive, individuals will continuously be replenished, by birth or immigration, thereby allowing the disease to sustain itself in the community).

It is convenient to define the following feasible (positively-invariant and attracting) region for the model (2.1)$$\text{Ω} = \left\{ {\left( {S_{u},S_{v},E_{1},E_{2},I_{s},I_{a},I_{h},R} \right) \in \mathbb{R}_{+}^{8}:S_{u} + S_{v} + E_{1} + E_{2} + I_{s} + I_{a} + I_{h} + R \leq N\left( 0 \right)} \right\}.$$

We claim the following result:Theorem 3.2*The continuum disease-free equilibria* ($\mathcal{E}_{0}$) *of the model* (2.1) *is globally-asymptotically stable in* $\text{Ω}$ *if* $\mathcal{R}_{c} \leq 1$.

The [Proof](#enun_Proof){ref-type="statement"} to [Theorem 3.2](#enun_Theorem_3_2){ref-type="statement"}, based on using Lyapunov function theory, is given in [Appendix A](#appsec1){ref-type="sec"}. Here, too, the requirement $\mathcal{R}_{c} \leq 1$ is sufficient, and not necessary, for the elimination of the pandemic. The epidemiological implication of this result is that COVID-19 elimination is independent of the initial sizes of the sub-populations of the model (i.e., the initial number of infected individuals introduced into the community does not have to be within the basin of attraction of the continuum of the disease-free equilibria, $\mathcal{E}_{0}$ of the model).

In the absence of control interventions (i.e., no face mask usage and vaccination) in the community vaccination, the control reproduction number ($\mathcal{R}_{c}$) (3.1) reduces to the basic reproduction number (denoted by $\mathcal{R}_{0}$), given by:$$\left. \mathcal{R}_{0} = \mathcal{R}_{c} \middle| {}_{c_{M} = \varepsilon_{M} = \varepsilon_{v} = S_{v}^{\ast} = 0} = \frac{\beta_{e}}{\sigma_{2}} + \frac{\left( {1 - r} \right)\beta_{s}}{\varphi_{s} + \gamma_{s} + \delta_{s}} + \frac{r\beta_{a}}{\gamma_{a}} \right.$$

The quantity $\mathcal{R}_{0}$ represents the average number of new infections generated by a typical COVID-19 infected individual introduced into a completely susceptible population during the duration of his/her infectiousness. It is convenient to define the following quantity$$\left. \mathcal{R}_{0}^{\text{∗}} = \mathcal{R}_{c} \middle| {}_{c_{M} = \varepsilon_{M} = 0} = \mathcal{R}_{0}\left\lbrack \frac{S_{u}^{\text{∗}} + \left( {1 - \varepsilon_{v}} \right)S_{v}^{\text{∗}}}{N^{\text{∗}}} \right\rbrack, \right.$$

which represents the control reproduction number of the model in the absence of face masks usage in the community.

3.2. Model fitting and parameter estimation {#sec3.2}
-------------------------------------------

Some of the parameters of the model (2.1) were obtained either from the literature, or assumed based on publicly-available COVID-19 related information ([Table 3](#tbl3){ref-type="table"}(a)). For the six parameters whose numerical values are not known, namely the community contact rates ($\beta_{e},\beta_{a}$ and $\beta_{s}$), the hospitalization rate of symptomatic individuals ($\varphi_{s}$), mask compliance ($c_{M}$), and the COVID-19-related mortality rate of hospitalized individuals ($\delta_{h}$), we estimated them using the COVID-19 mortality data for the US from March 1, 2020 to June 23, 2020 ([@bib6]; [@bib10], [@bib11]; [@bib10], [@bib11]; [@bib30]). Although the first documented COVID-19 case in the US was reported January 20, 2020 ([@bib17]), there were less than 30 confirmed cases in the US by March 1, 2020 ([@bib10], [@bib11]). Hence, we used data from March 1 onward in estimating our parameters, and we also start all our simulations from March 1. Also, since the mortality data was collected when no vaccination program is in place, we fitted these parameters to the special case of the model (2.1) without vaccination. To calibrate the six parameters, we used a nonlinear least squares method to determine the set of parameters that minimizes the sum of the squares of the differences between the cumulative death predictions of the vaccination-free version of the model (2.1) and the observed cumulative COVID-19 mortality. The result obtained is depicted in [Fig. 2](#fig2){ref-type="fig"} (left panel). Furthermore, the observed daily deaths are plotted alongside the predicted daily deaths generated using the vaccination-free version of the model (2.1) with the parameter values obtained from the fitting of the cumulative cases (right panel of [Fig. 2](#fig2){ref-type="fig"}). The values of the calibrated parameters obtained are tabulated in [Table 3](#tbl3){ref-type="table"}(b). Since no vaccine-related data for COVID-19 are currently available, we assumed that the hypothetical vaccine considered in this study has a baseline protective efficacy of 80% (i.e., we set $\varepsilon_{v} = 0.8$). Further, we assume the baseline value of the vaccination rate ($\xi_{v}$) is 0.0203 *per* day.Table 3Parameters of the model (2.1).Table 3(a) Parameter values from the literature (and those assumed)**ParameterDefault valuesReference**$\varepsilon_{M}$0.5 (dimensionless)Estimated from ([@bib8])$\varepsilon_{v}$0.8 (dimensionless)Assumed$\xi_{v}$0.0203 day^−1^Assumed$\sigma_{1}$1/4 day^−1^Adapted from ([@bib7])$\sigma_{2}$1/2 day^−1^Adapted from ([@bib7])R0.35$\gamma_{a}$1/7 day^−1^([@bib27]; [@bib33])$\gamma_{s}$1/7 day^−1^([@bib27]; [@bib33])$\gamma_{h}$1/14 day^−1^([@bib27]; [@bib33])$\delta_{s}$$\delta_{h}/3$ day^−1^Estimated(b) Fitted parameters**ParameterFitted value**$\beta_{e}$0.1004 day^−1^$\beta_{a}$0.7701 day^−1^$\beta_{s}$0.3214 day^−1^$\varphi_{s}$0.0514 day^−1^$c_{M}$0.1704 (dimensionless)$\delta_{h}$0.0001 day^−1^Fig. 2(a) Data fitting of the model (2.1) in the absence of vaccination using COVID-19 mortality data for the US ([@bib6]; [@bib30]). (b) Simulations of the model (2.1) (using the estimated parameters) illustrating the daily mortality curve. The red dots represent data points, while the solid blue line represent predictions of death from model (2.1) for the period between March 1, 2020 through June 23, 2020.Fig. 2

It is noteworthy from the fitted parameters in [Table 3](#tbl3){ref-type="table"} (b) that the sum of the fitted values of the community contact rates for the pre-symptomatic ($\beta_{e}$) and asymptomatically-infectious individuals ($\beta_{a}$) overwhelmingly exceeds that for the symptomatically-infectious individuals ($\beta_{s}$). Thus, our fitting suggests that pre-symptomatic and asymptomatic infectious individuals are the overwhelming drivers of the pandemic in the US. In other words, the vast majority of the COVID-19 infections in the US is caused by COVID-19-infected individuals who are unaware of their infection status (i.e., those in the $E_{2}$ and $I_{a}$ classes). Tindale et al. ([@bib28]) also showed that pre-symptomatic transmission played a significant role in COVID-19 dynamics in Singapore (accounting for 40-$50\text{\%}$ of transmissions) and Tianjin, China (60-$80\text{\%}$ of transmissions).

3.3. Vaccine-induced herd immunity threshold {#sec3.3}
--------------------------------------------

For vaccine-preventable diseases, not all susceptible individuals can be immunized for various reasons, such as they are too young to be vaccinated (vaccinating infants or young children can, sometimes, harm the infants/children), they have co-morbidities and weakened immune system (and vaccinating may make their prognosis worse), they are of advanced age or they opt out for cultural, traditional or religious reasons. The question then is what is the minimum proportion of those we can vaccinate that we need to vaccinate so that those that we cannot vaccinate can be protected from developing severe disease or dying of the disease. The notion of *herd immunity* in the transmission dynamics is associated with the indirect protection, against acquisition of a communicable disease, members of the community receive when a large percentage of the population has become immune to the infectious disease due to natural recovery from prior infection or vaccination ([@bib1]; [@bib2]). The consequence of herd immunity is that individuals who are not immune (e.g., those who cannot be vaccinated or those who have not been infected yet) receive some protection against the acquisition of the disease. The safest and fastest way to achieve herd immunity is obviously vaccination. It should, however, be mentioned that Sweden employed the other mechanism for achieving herd immunity in the context of COVID-19 dynamics in Sweden ([@bib15]). In other words, the Swedish public health agencies aimed to build herd immunity by not implementing the basic community transmission reduction strategies (e.g., social distancing, community lockdowns, use of face masks in public, contact tracing etc.) implemented in almost every country or community that is hard-hit with the COVID-19 pandemic, opting, instead, to allow individuals to acquire infection and, hopefully, recover from it. Although some level of this *natural herd immunity* has been achieved in Sweden, the COVID-induced mortality recorded in Sweden far exceed those recorded for neighbouring Scandinavian countries that implemented the aforementioned non-pharmaceutical interventions ([@bib15]).

In this section, a theoretical condition for achieving community-wide vaccine-induced herd immunity is derived. Let $f_{v} = \frac{S_{v}^{\text{∗}}}{N^{\text{∗}}}$ be the fraction of unvaccinated susceptible individuals that have been vaccinated at the disease-free steady-state. It follows that the control reproduction number ($\mathcal{R}_{c}$) can then be re-written, in terms of $f_{v}$, as follows:$$\mathcal{R}_{c} = \mathcal{R}_{0}\left( {1 - \varepsilon_{M}c_{M}} \right)\left\lbrack \frac{S_{u}^{\text{∗}} + \left( {1 - \varepsilon_{v}} \right)S_{v}^{\text{∗}}}{N^{\text{∗}}} \right\rbrack,$$

which can be simplified as (for the special case with $\mathcal{R}$\* being infinitesimally small in comparison to the total initial population N(0))$$\mathcal{R}_{c} \approx \mathcal{R}_{0}\left( {1 - \varepsilon_{M}c_{M}} \right)\left( {1 - \varepsilon_{v}f_{v}} \right).$$

Setting $\mathcal{R}_{c} = 1$ in [(3.6)](#fd3_6){ref-type="disp-formula"}, and solving for $f_{v}$, gives the following vaccine-induced herd immunity threshold for the model (2.1):$$f_{v} \approx \frac{1}{\varepsilon_{v}}\left\lbrack {1 - \frac{1}{\mathcal{R}_{0}\left( {1 - \varepsilon_{M}c_{M}} \right)}} \right\rbrack = f_{v}^{c},\ \ \text{with}\ \varepsilon_{M}c_{M} \neq 1.$$

It follows from [(3.6)](#fd3_6){ref-type="disp-formula"}, [(3.7)](#fd3_7){ref-type="disp-formula"} that $\mathcal{R}_{c} < \left( > \right)1$ whenever $f_{v} > \left( < \right)f_{v}^{c}$. This implies that if $f_{v} > f_{v}^{c}$, then the epidemic dies out (in line with Theorems 3.1 and 3.2). Furthermore, if $f_{v} < f_{v}^{c}$, then the epidemic rises, reaches a peak, and eventually declines to zero (in line with [Theorem 3.1](#enun_Theorem_3_1){ref-type="statement"}).

In order to obtain the projected value of the vaccine-derived community herd immunity threshold for the US, we compute the value of basic reproduction number ($\mathcal{R}_{0}$), from Equation [(3.3)](#fd3_3){ref-type="disp-formula"} and using the baseline values of the community contact rates ($\beta_{e}$, $\beta_{a}$ and $\beta_{s}$) and other parameters in [Table 2](#tbl2){ref-type="table"}. This gives $\mathcal{R}_{0} = 3.16$. Substituting this value of $\mathcal{R}_{0}$ into (3.7), and noting that the vaccine efficacy is assumed to be 80% (i.e., $\varepsilon_{v} = 0.8$) and the baseline values of face masks efficacy and compliance given in [Table 3](#tbl3){ref-type="table"} (i.e., $\varepsilon_{M} = 0.5$ and $c_{M} = 0.1704$, respectively), shows that the vaccine-derived community herd immunity threshold for the US is approximately 82% (see [Table 4](#tbl4){ref-type="table"}). The epidemiological implication of this result is that the pandemic can be effectively controlled (i.e., community transmission of COVID-19 can be significantly curtailed or the disease can be eliminated) if at least 82% of the susceptible US population is vaccinated.Table 4Community herd immunity threshold ($f_{v}$) for the US for various levels of mask compliance ($c_{M}$). Parameter values used are as given in [Table 3](#tbl3){ref-type="table"}.Table 4Mask compliance percentage ($c_{M}$)0%$10\text{\%}$17.04% (baseline)$30\text{\%}$$50\text{\%}$$100\text{\%}$Herd immunity threshold ($f_{v}$)85.4%83.4%$81.8\text{\%}$$78.5\text{\%}$$72.3\text{\%}$$45.9\text{\%}$

The aforementioned required vaccine coverage herd immunity percentage is certainly on the high side, and may not be realistically attainable. In fact, Dr. Anthony Fauci, a member of the US Presidential Task Force on COVID-19, stated on June 29, 2020 that the hypothetical anti-COVID-19 vaccine may not reach the required high immunity in the US if many people refuse to get it ([@bib3]). One way to get around this need for high vaccine coverage to achieve high immunity is to combine the vaccination program with another anti-COVID-19 intervention, such as the use of face masks in public. [Table 4](#tbl4){ref-type="table"} shows that the required herd immunity threshold decreased to (perhaps a more realistically-attainable) $72\text{\%}$ if half the US population wears face masks in public. Further, only 46% of the US population would need to be vaccinated if everyone wears face mask in public. Thus, these simulations show that combining the vaccination program (using the hypothetical anti-COVID-19 vaccine with assumed efficacy of 80%) with a public face mask use strategy significantly enhances the prospect of COVID-19 elimination in the US.

[Fig. 3](#fig3){ref-type="fig"} depicts the cumulative mortality as a function of time for various values of the steady-state vaccination coverage ($f_{v}$). This figure shows an increase in the cumulative mortality when $f_{v} < f_{v}^{c}$ and a decrease when $f_{v} > f_{v}^{c}$ (it should be mentioned that this figure was generated for the case where the vaccination program is implemented on March 1, 2020; this explains why the cumulative mortality numbers generated from the model are much lower than the mortality numbers actually recorded in the US over the same time period). It is worth mentioning that our results for the herd immunity threshold are subject to the homogeneous mixing assumption made in the formulation of the model (2.1). It is quite possible that the required herd immunity threshold for the US may change (i.e., be lower than what we estimated) if the homogeneous mixing assumption is relaxed (i.e., if heterogeneities in mixing, perhaps based on age or socio-economic status, is incorporated into the model).Fig. 3Simulations of the model (2.1), showing the cumulative COVID-19 mortality as a function of time for various levels of herd immunity threshold ($f_{v}$). (a) $f_{v} < f_{v}^{c}\ \left( r = 0.2 \right)$ (b) $f_{v} = f_{v}^{c}\ \left( r = 0.35 \right)$ (c) $f_{v} > f_{v}^{c}\ \left( r = 0.7 \right)$. Other parameter values used are as given in [Table 3](#tbl3){ref-type="table"}. For these simulations, the vaccination program is assumed to be implemented at the onset of the pandemic (starting March 1, 2020).Fig. 3

4. Numerical simulations of vaccine impact {#sec4}
==========================================

The model (2.1) is now simulated to assess the population-level impact of the hypothetical imperfect anti-COVID-19 vaccine in the US. The population-level impact of the vaccination rate ($\xi_{v}$) on the burden of the pandemic is monitored first of all. In these simulations, the public face mask use strategy is not implemented. The model (2.1) is then simulated using the baseline parameter values in [Table 3](#tbl3){ref-type="table"} (with $c_{M} = \varepsilon_{M} = 0$) and various values of $\xi_{v}$. The results obtained, depicted in [Fig. 4](#fig4){ref-type="fig"}, show that, for the worst-case scenario without vaccination and face masks usage in public (i.e., the model (2.1) with $\xi_{v} = S_{v} = \varepsilon_{M} = c_{M} = 0$), the US could record up to 110,000 cumulative deaths at the pandemic peak [Fig. 4](#fig4){ref-type="fig"}(a). The corresponding projected daily mortality is 2400 [Fig. 4](#fig4){ref-type="fig"}(b). These simulations show a dramatic reduction in the cumulative and the daily COVID-induced mortality (in comparison to the worst-case scenario without vaccination and mask usage) with increasing values of the vaccination rate $\xi_{v}$ (from its baseline value). In particular, a 10% increase in the baseline value of $\xi_{v}$ for the US resulted in a decrease in the cumulative number of deaths at the pandemic peak from 120,000 to 46,000 ([Fig. 4](#fig4){ref-type="fig"} (a)). Furthermore, this corresponds to a decrease in the projected daily mortality from 2400 to 700, representing a $71\text{\%}$ reduction ([Fig. 4](#fig4){ref-type="fig"} (b)). Similarly, a 30% increase in the baseline value of $\xi_{v}$ resulted in a marked reduction of the daily deaths at the pandemic peak to 580 (corresponding to a decrease in the projected cumulative mortality from 120,000 to 25,000). Thus, these simulations suggest that a significantly large increase in vaccination rate (from baseline) is necessarily needed to eliminate COVID-19 in the US using the hypothetical vaccine.Fig. 4Effect of vaccination coverage. Simulations of the model (2.1) showing the effect of the vaccination rate ($\xi_{v}$) on COVID-19 burden measure in terms of (a) cumulative deaths and (b) daily deaths. Parameter values used are as given in [Table 3](#tbl3){ref-type="table"}, with $c_{M} = \varepsilon_{M} = 0$ and various values of $\xi_{v}$.Fig. 4

The model (2.1) is simulated to allow for the assessment of the impact of social distancing measures (aimed at reducing community transmission) with the implementation of vaccination and public mask usage in the community. We consider three levels of social distancing effectiveness, namely mild, moderate and high (strict). We model these effectiveness levels in terms of reduction in the community contact rate parameters ($\beta_{e}$, $\beta_{a}$ and $\beta_{s}$), in comparison to their baseline values. In particular, we set mild, moderate, and strict (high) social distancing to correspond to a 10%, 30%, and 50% reduction, respectively, in the values of the contact rate parameters, in relation to their baseline values in [Table 3](#tbl3){ref-type="table"}. The simulation results obtained, depicted in [Fig. 5](#fig5){ref-type="fig"}, shows a marked decrease in disease burden (measured in terms of daily and cumulative COVID-induced mortality) with increasing effectiveness of social distancing, as expected. For instance, while [Fig. 5](#fig5){ref-type="fig"} shows that up to 51,000 cumulative mortality can be recorded if social distancing measures were not implemented, the cumulative mortality dramatically decreases to about 5000 (representing about $90\text{\%}$ reduction in cumulative mortality) if strict social distancing measures were implemented ([Fig. 5](#fig5){ref-type="fig"} (a)). Similarly, [Fig. 5](#fig5){ref-type="fig"} shows that up to 810 daily mortality can be recorded in the US if social distancing measures were not implemented, the daily mortality dramatically decreases to about 70 (representing about $91\text{\%}$ reduction in daily mortality) if strict social distancing measures were implemented ([Fig. 5](#fig5){ref-type="fig"} (b)). Thus, these simulations suggest that the implementation of the vaccination program alongside mask use and social distancing is more effective than if only the first two strategies are used.Fig. 5Simulations of the model (2.1) for the impact various effectiveness of social distancing control measures in the presence of vaccination on (a) cumulative deaths, (b) daily deaths. Mild, moderate, and strict (high) social distancing corresponds to 10%, 30%, and 50%, decrease in the values of the community contact rates $\beta_{e}$, $\beta_{a}$, and $\beta_{s}$ from their baseline values, respectively. Parameter values used are as given in [Table 3](#tbl3){ref-type="table"}.Fig. 5

Simulations were also carried out to assess the impact of vaccine efficacy and coverage on this disease dynamics. This is done for the special case of the model in the absence of the use of masks in the public (i.e., the model (2.1) with $c_{M} = \varepsilon_{M} = 0$). Specifically, a contour plot of the control reproduction number ($\mathcal{R}_{c}$) of the model, as a function of coverage ($\left. f_{v} \right)$ and vaccine efficacy ($\varepsilon_{v}$), is depicted in [Fig. 6](#fig6){ref-type="fig"}. This figure shows a decrease in the value of the reproduction number with increasing coverage and efficacy of the vaccine, as expected. For the assumed 80% efficacy of the hypothetical vaccine (i.e., $\left. \varepsilon_{v} = 0.8 \right)$ in [Table 3](#tbl3){ref-type="table"} (a), the simulations depicted in [Fig. 6](#fig6){ref-type="fig"} show that nationwide elimination of COVID-19 can be achieved (i.e., $\mathcal{R}_{0}^{\text{∗}}$ can be brought to a value below unity) if at least 85.4% of the US populace is vaccinated.Fig. 6Effects of vaccination as the only intervention strategy. Contour plots of the control reproduction number ($\mathcal{R}_{c}$) of the model (2.1), as a function of vaccine coverage ($f_{v}$) and vaccine efficacy ($\varepsilon_{v}$), for the baseline scenarios in [Table 3](#tbl3){ref-type="table"} and in the absence of mask usage in public for the US. Parameter values used are as given in [Table 3](#tbl3){ref-type="table"} with $\varepsilon_{M} = c_{M} = 0$.Fig. 6

The effect of the combined implementation of vaccination and social distancing strategies, on the control reproduction number ($\mathcal{R}_{c}$) of the model (2.1), is also monitored, by generating contour plots of $\mathcal{R}_{c}$, as a function of vaccination coverage ($f_{v}$) and efficacy ($\varepsilon_{v}$), for the aforementioned three levels (low, moderate and high) of social distancing effectiveness. The results obtained, depicted in [Fig. 7](#fig7){ref-type="fig"}, show that COVID-19 elimination (measured in terms of bringing $\mathcal{R}_{c}$ to a value less than unity) is feasible even if social distancing is implemented at a low (mild) level of effectiveness (left panels of [Fig. 7](#fig7){ref-type="fig"}). In particular, [Fig. 7](#fig7){ref-type="fig"} (a) shows that, with the assumed 80% efficacy of the vaccine, the implementation of social distancing at low effectiveness level will lead to the elimination of COVID-19 if the vaccine coverage is at least 81%. This required coverage decreases with increasing effectiveness of the social distancing measures ([Fig. 7](#fig7){ref-type="fig"} (b) and (c)).Fig. 7Effect of combined vaccination and social distancing strategies. Contour plots of the control reproduction number ($\mathcal{R}_{c}$), as a function of vaccine coverage ($f_{v}$) and vaccine efficacy ($\varepsilon_{v}$) for the special case of the model (2.1) with no mask use in public. (a) mild social distancing (i.e., 10$\text{\%}$ decrease in $\beta_{e}$, $\beta_{s}$ and $\beta_{a}$). (b) Moderate social distancing (i.e., 30$\text{\%}$ decrease in $\beta_{e}$, $\beta_{s}$ and $\beta_{a}$). (c) Strict social distancing (i.e., 50$\text{\%}$ decrease in $\beta_{e}$, $\beta_{s}$ and $\beta_{a}$). Parameter values used are as given in [Table 3](#tbl3){ref-type="table"}.Fig. 7

Additional numerical simulations were carried out to assess the community-wide impact of the combined impact of vaccination with a public face mask use strategy (as measured in terms of reduction in the value of control reproduction number, $\mathcal{R}_{c}$). The results obtained, depicted in [Fig. 8](#fig8){ref-type="fig"}, show a decrease in $\mathcal{R}_{c}$ with increasing vaccine efficacy and compliance. For the fixed vaccine efficacy at 80%, our results show that if 10% of the US population wear face masks in public, the minimum vaccine coverage needed to eliminate the disease is approximately 83%. The minimum coverage needed to eliminate the pandemic decreases to 79% and 72%, respectively, if 30% and 50% of the US population wear face masks in public ([Fig. 8](#fig8){ref-type="fig"} (a), (b) and (c)). Thus, the simulations in [Fig. 7](#fig7){ref-type="fig"}, [Fig. 8](#fig8){ref-type="fig"} also emphasize the fact that the prospect of COVID-19 elimination using a vaccine is greatly enhanced if the vaccination program is complemented with another anti-COVID-19 intervention (such as face masks usage in public and social distancing), particularly if the complementary intervention is implemented at moderate or high effectiveness level (i.e, implemented universally, and with high efficacy and compliance).Fig. 8Contour plots of the control reproduction number ($\mathcal{R}_{c}$), as a function of vaccine coverage ($f_{v}$) and vaccine efficacy ($\varepsilon_{v}$) for (a) 10% mask compliance, (b) 30$\text{\%}$ mask compliance, and (c) 50$\text{\%}$ mask compliance. Parameter values used are as given in [Table 3](#tbl3){ref-type="table"} with various values of $c_{M}$.Fig. 8

5. Discussion and conclusions {#sec5}
=============================

A novel Coronavirus (COVID-19) emerged in China in December 2019. The virus, which is caused by SARS-CoV-2, rapidly spread to over 210 countries causing over 10 million confirmed cases and 500,000 deaths globally (as of June 28, 2020). Although there are currently no safe and effective vaccine for use in humans, numerous concerted global efforts are underway aimed at developing such vaccine. In fact, a number of candidate vaccines are undergoing advanced stages of clinical trials. One of the most promising of these efforts is the candidate vaccine being developed by a research group at Oxford University, which is expected to be available as early as January 2021 (or, latest, by the spring of 2021). We developed a mathematical model for assessing the potential community-wide impact of a hypothetical imperfect vaccine against the COVID-19 pandemic in the US. The model we developed, which takes the form of a deterministic system of nonlinear differential equations, was parametrized using COVID-19 data for the US. The hypothetical vaccine was assumed to offer imperfect protective efficacy against the acquisition of COVID-19 infection.

The model was rigorously analysed to gain insight into its dynamical features. These analyses reveal that the continuum of disease-free equilibria of the epidemic model is asymptotically-stable whenever a certain epidemiological threshold, known as the control reproduction number (denoted by $\mathcal{R}_{c}$), is less than unity. The epidemiological implication of this result is that the community transmission of COVID-19 can be significantly curtailed if $\mathcal{R}_{c} < 1$. In other words, the routine vaccination against COVID-19 (using the hypothetical vaccine) can lead to the effective control or elimination of the pandemic if it can bring (and maintain) $\mathcal{R}_{c}$ to a value less than unity. Furthermore, threshold quantities for the community vaccine-induced herd immunity were calculated. Our computations show, using the baseline values of the parameters of the model, that at least 82% of the US population needs to be vaccinated in order to achieve nationwide vaccine-derived herd immunity. This required vaccine coverage is certainly on the high side, and may not be easily attained for so many reasons, ranging from the expected insufficient stockpile of the vaccine during the early stages of their deployment, general apathy towards vaccination and the sizable percentage of people that cannot be vaccinated for medical, personal and other reasons (in fact, Dr. Anthony Fauci, a member of the US Presidential Task Force on COVID-19 warned on June 28, 2020 that the hypothetical vaccine may not generate the required level of herd immunity if too many people in the US decide not to be vaccinated ([@bib3])). Our simulations showed that if the vaccination strategy is complemented with other public health interventions, such as a public mask use strategy for instance, the minimum herd immunity threshold required to effectively control the COVID-19 pandemic significantly reduces to a more realistically-attainable level. For example, if vaccination (using a vaccine with the assumed efficacy of 80%) is combined with a public face mask strategy with 30% mask compliance nationwide, the herd immunity threshold for the entire US decreases to 79%. In fact, this threshold decreases to only 46% if everyone in the US (who can wear a face mask) wears face mask in public. Thus, this study shows that the prospect of the effective control of COVID-19 using routine vaccination (with the hypothetical vaccine) is significantly enhanced if the vaccination program is combined with a public face mass use strategy (especially if the effectiveness and coverage of the face mask use strategy are high enough).

We also carried out numerical simulations to measure the population-level impact of the rate at which the hypothetical vaccination is administered. The results obtained showed that the COVID-19 burden (as measured in terms of daily and cumulative COVID-induced mortality) decreases with increasing vaccination rate, as expected. Our simulations showed that high increases in the vaccination rate (from its baseline value) is necessarily needed to achieve significant reduction in disease burden. We also simulated the combined effect of implementing the routine vaccination program with social distancing (in the absence of face mask usage). We showed that COVID-19 can be effectively controlled using the two interventions even if the effectiveness level of social distancing is low (as long as the vaccine coverage is high). In particular, our simulations showed that the control reproduction number ($\mathcal{R}_{c}$) can be reduced to a value less than unity (needed for the effective control of the disease, in line with the local and global asymptotic stability property of the continuum of disease-free equilibria, established in Section [3](#sec3){ref-type="sec"}).

We assessed the population-level impact of combining the routine vaccination strategy with a public mask use strategy. Our simulations show a decrease in the burden of the COVID-19 pandemic (again as measured in terms of reduction in the value of the reproduction number $\mathcal{R}_{c}$) with increasing efficacies and compliance of the vaccine and mask usage. It was shown that if the vaccine efficacy is fixed at the assumed 80% and mask compliance is fixed at the low value of 10%, COVID-19 can be eliminated if the vaccine coverage is at least 83%. The vaccine coverage decreases to 79%, 72%, and 46%, respectively, if mask use compliance is increased to 30%, 50%, and 100%. Again, these result confirmed that COVID-19 elimination is more feasible if the vaccination program is combined with another intervention (face mask use in public, in this case).

In summary, this study shows that the prospect of eliminating COVID-19 in the US using the imperfect hypothetical vaccine is promising. This prospect is greatly enhanced if the vaccination program is combined with other interventions that limit community transmission, such as social distancing and face mask use in public. Certain factors may affect the results we presented in this study. The first is that the absence of vaccine-related data forced us to make assumptions on the expected efficacy of the hypothetical vaccine ($\varepsilon_{v}$), as well as the rate at which it will be administered in the US ($\xi_{v}$). In particular, we assumed a vaccine efficacy of $80\text{\%}$, which may be higher than the efficacy of the COVID-19 vaccine we end up having in the future. Second, the model we developed in this study is based on assuming a well-mixed population. This simplifying homogeneous-mixing assumption (needed for mathematical tractability) constitutes another limitation of the study (in particular, the value for the vaccine-derived herd immunity threshold we estimated may be lowed if mixing heterogeneities are incorporated into the model). The authors plan to address these heterogeneities in a future study.
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Appendix A. Proof of [Theorem 3.2](#enun_Theorem_3_2){ref-type="statement"} {#appsec1}
===========================================================================

ProofConsider the model (2.1) with $\mathcal{R}_{c} \leq 1$. Furthermore, consider the following linear Lyapunov function:$$\mathcal{L} = g_{1}E_{1} + g_{2}E_{2} + g_{3}I_{s} + g_{4}I_{a},$$where,$$g_{1} = \gamma_{a}\left( {\varphi_{s} + \gamma_{s} + \delta_{s}} \right),\ g_{2} = g_{1},\ g_{3} = \gamma_{a}\beta_{s}\left( {1 - \varepsilon_{M}c_{M}} \right)\ \text{and}\ \text{g}_{4} = \left( {\varphi_{\text{s}} + \gamma_{\text{s}} + \delta_{\text{s}}} \right)\beta_{\text{a}}\left( {1 - \varepsilon_{\text{M}}\text{c}_{\text{M}}} \right)$$It follows that the Lyapunov derivative is given by:$${\overset{˙}{\mathcal{L}} = g_{1}{\overset{˙}{E}}_{1} + g_{2}{\overset{˙}{E}}_{2} + g_{3}{\overset{˙}{I}}_{s} + g_{4}{\overset{˙}{I}}_{a},}{= g_{1}\left\lbrack \left( {\lambda_{e} + \lambda_{s} + \lambda_{a}} \right)\left\lbrack S_{u} + \left( {1 - \varepsilon_{v}} \right)S_{v} \right\rbrack - \sigma_{1}E_{1} \right\rbrack + g_{2}\left\lbrack \sigma_{1}E_{1} - \sigma_{2}E_{2} \right\rbrack + g_{3}\left\lbrack \left( {1 - r} \right)\sigma_{2}E_{2} - \left( {\varphi_{s} + \gamma_{s} + \delta_{s}} \right)I_{s} \right\rbrack}{+ g_{4}\left\lbrack r\sigma_{2}E_{2} - \gamma_{a}I_{a} \right\rbrack,}{= g_{1}\left\lbrack \beta_{e}\left( {1 - \varepsilon_{M}c_{M}} \right)\frac{E_{2}}{N}\left( {S_{u} + \left( {1 - \varepsilon_{v}} \right)S_{v}} \right) \right\rbrack - g_{2}\sigma_{2}E_{2} + g_{3}\left( {1 - r} \right)\sigma_{2}E_{2} + g_{4}r\sigma_{2}E_{2}}{+ g_{1}\left\lbrack \beta_{a}\left( {1 - \varepsilon_{M}c_{M}} \right)\frac{I_{a}}{N}\left( {S_{u} + \left( {1 - \varepsilon_{v}} \right)S_{v}} \right) \right\rbrack - g_{4}\gamma_{a}I_{a}}{+ g_{1}\left\lbrack \beta_{s}\left( {1 - \varepsilon_{M}c_{M}} \right)\frac{I_{s}}{N}\left( {S_{u} + \left( {1 - \varepsilon_{v}} \right)S_{v}} \right) \right\rbrack - g_{3}\left( {\varphi_{s} + \gamma_{s} + \delta_{s}} \right)I_{s},}$$which can be simplified to,$$\begin{array}{lll}
\overset{˙}{\mathcal{L}} & = & {\gamma_{a}\left( {\phi_{s} + \gamma_{s} + \delta_{s}} \right)\left\lbrack \beta_{s}\left( {1 - \varepsilon_{M}c_{M}} \right)\frac{I_{s}}{N}\left( {S_{u} + \left( {1 - \varepsilon_{v}} \right)S_{v}} \right) \right\rbrack - \gamma_{a}\beta_{s}\left( {1 - \varepsilon_{M}c_{M}} \right)\left( {\phi_{s} + \gamma_{s} + \delta_{s}} \right)I_{s}} \\
 & + & {\gamma_{a}\left( {\phi_{s} + \gamma_{s} + \delta_{s}} \right)\left\lbrack \beta_{a}\left( {1 - \varepsilon_{M}c_{M}} \right)\frac{I_{a}}{N}\left( {S_{u} + \left( {1 - \varepsilon_{v}} \right)S_{v}} \right) \right\rbrack - \left( {\phi_{s} + \gamma_{s} + \delta_{s}} \right)\beta_{s}\left( {1 - \varepsilon_{M}c_{M}} \right)\gamma_{a}I_{a}} \\
 & + & {\gamma_{a}\left( {\phi_{s} + \gamma_{s} + \delta_{s}} \right)\sigma_{2}\left\{ {\frac{\beta_{e}\left( {1 - \varepsilon_{M}c_{M}} \right)\left\lbrack S_{u} + \left( {1 - \varepsilon_{v}} \right)S_{v} \right\rbrack}{\sigma_{2}N} + \frac{\left( {1 - r} \right)\beta_{s}\left( {1 - \varepsilon_{M}c_{M}} \right)}{\left( {\phi_{s} + \gamma_{s} + \delta_{s}} \right)} + \frac{r\beta_{a}\left( {1 - \varepsilon_{M}c_{M}} \right)}{\gamma_{a}} - 1} \right\} E_{2},} \\
\end{array}$$so that (noting that since $S_{u}\left( 0 \right) + S_{v}\left( 0 \right) \leq N\left( t \right)$ in $\text{Ω}$ and $0 \leq \varepsilon \leq 1$, then $S_{u}\left( t \right) + \left( {1 - \varepsilon_{v}} \right)S_{v}\left( t \right) \leq N\left( t \right)$ for all *t*),$${\overset{˙}{\mathcal{L}} \leq \gamma_{a}\left( {\varphi_{s} + \gamma_{s} + \delta_{s}} \right)\sigma_{2}\left\{ {\frac{\beta_{e}\left( {1 - \varepsilon_{M}c_{M}} \right)}{\sigma_{2}} + \frac{\left( {1 - r} \right)\beta_{s}\left( {1 - \varepsilon_{M}c_{M}} \right)}{\left( {\varphi_{s} + \gamma_{s} + \delta_{s}} \right)} + \frac{r\beta_{a}\left( {1 - \varepsilon_{M}c_{M}} \right)}{\gamma_{a}} - 1} \right\} E_{2},}{\leq \gamma_{a}\left( {\varphi_{s} + \gamma_{s} + \delta_{s}} \right)\sigma_{2}\left( {\mathcal{R}_{c} - 1} \right)E_{2}.}$$Hence, $\overset{˙}{\mathcal{L}} \leq 0$ if $\mathcal{R}_{c} \leq 1$, and $\overset{˙}{\mathcal{L}} = 0$ if and only if $E_{2}\left( t \right) = 0$. Therefore, $\mathcal{L}$ is a Lyapunov function for system (2.1). Substituting $E_{2}\left( t \right) = 0$ in the model (2.1) shows that $\left. \left( {S_{u}\left( t \right),S_{v}\left( t \right),E_{1}\left( t \right),E_{2}\left( t \right),I_{s}\left( t \right),I_{a}\left( t \right),I_{h}\left( t \right),R\left( t \right)} \right)\rightarrow\left( {S_{u}^{\text{∗}},S_{v}^{\text{∗}},0,0,0,0,0,R^{\text{∗}}} \right) \right.$ as $\left. t\rightarrow\infty \right.$. Furthermore, it can be shown that the largest compact invariant set in $\left\{ {\left( {S_{u}\left( t \right),S_{v}\left( t \right),E_{1}\left( t \right),E_{2}\left( t \right),I_{s}\left( t \right),I_{a}\left( t \right),I_{h}\left( t \right),R\left( t \right)} \right) \in \text{Ω}:\overset{˙}{\mathcal{L}} = 0} \right\}$ is the continuum of disease-free equilibria ($\mathcal{E}_{0}$). Hence, it follows, by the LaSalle's Invariance Principle, that the continuum of disease-free equilibria of the model (2.1) is a stable global attractor in $\text{Ω}$ whenever $\mathcal{R}_{c} \leq 1$.
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